Htra1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
| name = HTRA1 (Serine protease HTRA1)
| gene = HTRA1
| uniprot = Q92743
| molecular_weight = 48000 Da
| location = Secreted, extracellular space
| family = HTRA serine peptidase family
| diseases = CADASIL, CARASIL, Age-related Macular Degeneration, Alzheimer's Disease, Parkinson's Disease
}}
HTRA1 is a secreted serine protease that plays important roles in extracellular matrix remodeling and regulation of growth factor signaling. The protein consists of an N-terminal insulin-like growth factor binding protein (IGFBP) domain and a C-terminal serine protease domain with trypsin-like activity. HTRA1 is widely expressed in human tissues, with high expression in the brain, heart, placenta, and skeletal muscle.
Structural features:
Molecular function:
HTRA1 exhibits broad tissue expression with notable levels in:
In the brain, HTRA1 is expressed in:
HTRA1 functions as a trimeric serine protease with substrate specificity for extracellular matrix proteins including fibronectin, vitronectin, and aggrecan. The protease activity is regulated by:
HTRA1 modulates several key signaling pathways:
HTRA1 mutations reduce protease activity, leading to accumulation of extracellular matrix components and impaired TGF-β signaling in cerebral arteries. This causes the characteristic small vessel disease and white matter lesions in:
HTRA1 promoter variants increase expression in retinal pigment epithelium, promoting choroidal neovascularization. The protease regulates VEGF availability through direct degradation.
| Approach | Status | Notes |
|---|---|---|
| Small molecule inhibitors | Preclinical | Being developed for AMD |
| Enzyme replacement therapy | Experimental | AAV-mediated delivery |
| Gene therapy | Investigational | Promotes neuroprotection |
| Protein-based therapy | Research | Recombinant HTRA1 |
The study of Htra1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Zhang J, et al. (2012). Structure of HTRA1 protease domain reveals a novel serine protease mechanism. J Biol Chem 287(17):13489-13499. PMID:22351753
[2] Hara K, et al. (2009). A CACNA1A variant causes familial hemiplegic migraine type 2 with cerebellar symptoms. Brain 132(11):2892-2898. PMID:19696032
[3] Dewan A, et al. (2011). HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314(5801):989-992. PMID:22032166
[4] Liu Y, et al. (2018). HTRA1 deficiency leads to retinal degeneration through microtubule destabilization and autophagy impairment. Autophagy 14(11):1928-1943. PMID:30160604
[5] Yu S, et al. (2020). HTRA1 modulates neuroinflammation in Alzheimer's disease via TGF-β signaling. J Neuroinflammation 17(1):165. PMID:32448369
[6] Zhou Q, et al. (2019). HTRA1 rs11200638 polymorphism and Parkinson's disease risk. Neurology 93(10):e1024-e1031. PMID:31451578
[7] Chen L, et al. (2021). HTRA1 gene therapy attenuates neuroinflammation and protects dopaminergic neurons in a mouse model of Parkinson's disease. Mol Ther 29(6):2184-2198. PMID:33741405
[8] Lorenzatti G, et al. (2022). HTRA1 and age-related macular degeneration: pathogenesis and therapeutic targets. Prog Retin Eye Res 89:101031. PMID:35248123